

Request Information

Permalink

# Tetracosapentaenoic Acid Treatment for AMD, Diabetic Retinopathy and Glaucoma

Tech ID: 33747 / UC Case 2023-786-0

## BRIEF DESCRIPTION

An innovative approach using tetracosapentaenoic acid to treat age-related eye disorders by replenishing critical lipids in the retina.

## FULL DESCRIPTION

Researchers at UC Irvine have developed a method using tetracosapentaenoic acid to address age-related eye disorders such as age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma. This approach focuses on increasing the production of very long chain polyunsaturated acids (VLC-PUFAs) and docosahexaenoic acid (DHA), essential lipids that diminish with age, thereby improving retinal function and vision health.

## SUGGESTED USES

- » Treatment for various age-related eye disorders
- » Supplementation for individuals with decreased VLC-PUFA and DHA production due to aging
- » Potential application in preventive treatments for populations at risk of developing age-related eye conditions

## ADVANTAGES

- » Directly increases VLC-PUFA and DHA production, essential for retina health.
- » More effective delivery method compared to oral medications.
- » Provides a direct, specific, and reproducible method to deliver the active compound to the retina.
- » Addresses the underlying cause of lipid decrease in aging retinas.

## PATENT STATUS

Patent Pending

## CONTACT

Patricia H. Chan  
patricia.chan@uci.edu  
tel: 949-824-6821.



## OTHER INFORMATION

### CATEGORIZED AS

- » **Medical**
  - » Disease: Ophthalmology and Optometry
  - » Therapeutics

### RELATED CASES

2023-786-0

**UCI** Beall  
Applied Innovation

5270 California Avenue / Irvine, CA  
92697-7700 / Tel: 949.824.2683



© 2024, The Regents of the University of  
California  
[Terms of use](#)  
[Privacy Notice](#)